MAIA Biotechnology, Inc.

MAIA · NYSE · SIC 2834: Pharmaceutical Preparations
147
SEC Filings

Business Summary

PART I . Our Company MAIA Biotechnology, Inc. (MAIA, the Company, we, or us) is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Ateganosine (THIO, 6-thio-dG or 6-thio-2 -deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In July 2022, the first patient was administered with ateganosine in our Phase 2 human trial (THIO-101) in Australia. In December 2022, reg...

Next Earnings

Q2 FY2026 — expected 2026-09-26

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionMAIAdiscussed_in_filing Cybersecurity
topic_mentionMAIAdiscussed_in_filing Trusted Computing
topic_mentionMAIAdiscussed_in_filing Blockchain & Crypto
topic_mentionMAIAdiscussed_in_filing Regulation
topic_mentionMAIAdiscussed_in_filing Cybersecurity
topic_mentionMAIAdiscussed_in_filing Trusted Computing
topic_mentionMAIAdiscussed_in_filing Blockchain & Crypto
topic_mentionMAIAdiscussed_in_filing Regulation
topic_mentionMAIAdiscussed_in_filing Cybersecurity
topic_mentionMAIAdiscussed_in_filing Trusted Computing
topic_mentionMAIAdiscussed_in_filing Blockchain & Crypto
topic_mentionMAIAdiscussed_in_filing Regulation
topic_mentionMAIAdiscussed_in_filing Cybersecurity
topic_mentionMAIAdiscussed_in_filing Trusted Computing
topic_mentionMAIAdiscussed_in_filing Blockchain & Crypto
topic_mentionMAIAdiscussed_in_filing Regulation

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-232025-12-310001493152-26-012088EDGAR113K words
2025-03-212024-12-310000950170-25-043190EDGAR—
2024-03-212023-12-310000950170-24-034764EDGAR—
2023-03-242022-12-310000950170-23-009766EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-072025-09-300001493152-25-021272EDGAR32K words
2025-08-112025-06-300001641172-25-022899EDGAR—
2025-05-092025-03-310000950170-25-068005EDGAR—
2024-11-122024-09-300000950170-24-125474EDGAR—
2024-08-092024-06-300000950170-24-094747EDGAR—
2024-05-142024-03-310000950170-24-059550EDGAR—
2023-11-072023-09-300000950170-23-059778EDGAR—
2023-08-082023-06-300000950170-23-039399EDGAR—
2023-05-082023-03-310000950170-23-018480EDGAR—
2022-11-092022-09-300000950170-22-023956EDGAR—
2022-08-222022-06-300000950170-22-017637EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-020001493152-26-014924EDGAR1K words
2026-03-310001493152-26-013879EDGAR—
2026-03-270001493152-26-013088EDGAR—
2026-03-040001493152-26-008897EDGAR—
2026-02-240001493152-26-007831EDGAR—
2026-01-200001493152-26-002883EDGAR—
2026-01-130001493152-26-002085EDGAR—
2025-12-170001493152-25-028041EDGAR—
2025-12-110001493152-25-027244EDGAR—
2025-12-100001493152-25-027072EDGAR—

147 total filings indexed. 122 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001878313
TickerMAIA
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: e18fb948ea21558ddf082b9c107816223d91fded7753334a8f285c91fac43ef9
parent: 87afc1bfe169d88aa2ab008949d50ccd1357dab2825aec3c936772bda641c2c5
content hash: 7483e5213a4a46192289a33b4dee77161b005773c4927d1a753aa1246995ed0b
signed: 2026-04-13T04:46:09.429Z
sources: 15 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf